1            Bell J, Ringall A, Khezrian M, et al. An assessment of pressurized metered-dose inhaler use in countries in Europe and the rest of the world. Am J Respir Crit Care Med. 2023; 207: A6315.

2            Chandel A, Goyal AK, Ghosh G, et al. Recent advances in aerosolised drug delivery. Biomed Pharmacother. 2019; 112: 108601.

3            GWP 100 in Table 7.SM.6 Greenhouse Gas Lifetimes, Radiative Efficiencies and Metrics, 7SM The Earth’s Energy Budget, Climate Feedbacks and Climate Sensitivity Supplementary Material. Available from: https://www.ipcc.ch/report/ar6/wg1/downloads/report/IPCC_AR6_WGI_Chapter07_SM.pdf

4            Hargreaves C, Budgen N, Whiting A, et al. A new medical propellant HFO-1234ze(E): reducing the environmental impact of inhaled medicines. Thorax: A38–A39.

5            Amendment to EU F-gas regulation: Amending Directive (EU) 2019/1937 and repealing Regulation (EU) No 517/2014. 2024; Available from: https://eur-lex.europa.eu/eli/reg/2024/573/oj

6            ECHA publishes PFAS restriction proposal. 2023; Available from: https://echa.europa.eu/-/echa-publishes-pfas-restriction-proposal

7            FIRS Increasing Access to Inhaled Medicines for COPD and Asthma. Available from: https://ginasthma.org/firs-increasing-access-to-inhaled-medicines-for-copd-and-asthma/

8            Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma [Internet] 2024; Available from: https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf

9            Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. GOLD Report [Internet] 2025; Available from: file:///C:/Users/ruthb/Downloads/GOLD-2025-Report-v1.0-15Nov2024_WMV.pdf

10         World Health Organization Essential Medicines List. Drug Delivery Devices and Therapeutic Systems [Internet] 2023; Available from: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02

11         Laube BL, Janssens HM, de Jongh FHC, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011; 37: 1308–1331.

12         Mahler DA, Demirel S, Hollander R, et al. High Prevalence of Suboptimal Peak Inspiratory Flow in Hospitalized Patients With COPD: A Real-world Study. Chronic Obstr Pulm Dis. 2022; 9: 427–438.

13         Mortimer K, Reddel HK, Pitrez PM, et al. Asthma management in low and middle income countries: case for change. Eur Respir J. 2022;60(3):2103179.

14         Steiropoulos P, Bakakos P, Hatziagorou E, et al. The present and future of inhalation therapy for the management of obstructive airway diseases: emphasis on pressurized metered-dose inhalers. Pneumon. 2021; 34: 24.

15         Björnsdóttir US, Gizurarson S, Sabale U. Potential negative consequences of non-consented switch of inhaled medications and devices in asthma patients. Int J Clin Pract. 2013; 67: 904–910.

16         Usmani OS, Scullion J, Keeley D. Our planet or our patients-is the sky the limit for inhaler choice? Lancet Respir Med. 2019; 7: 11–13.

17         Small M, Anderson P, Vickers A, et al. Importance of inhaler-device satisfaction in asthma treatment: real-world observations of physician-observed compliance and clinical/patient-reported outcomes. Adv Ther. 2011; 28: 202–212.

18         Usmani OS, Levy ML. Effective respiratory management of asthma and COPD and the environmental impacts of inhalers. NPJ Prim Care Respir Med. 2023; 33: 24.

19         Molimard M, Le Gros V. Impact of patient-related factors on asthma control. J Asthma.  2008; 45: 109–113.

20         Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol. 2004; 114: 1288–1293.

21         Pritchard J, Usmani O. The greenest inhaler: a patient centric approach. EMJ Respir. 2022; 10: 2–7.

22         Attar-Zadeh D, Lewis H, Orlovic M. Health-care Resource Requirements and Potential Financial Consequences of an Environmentally Driven Switch in Respiratory Inhaler Use in England. J Health Econ Outcomes Res. 2021; 8: 46–54.

23         Usmani O, Roche N, Van Boven JFM, et al. Consensus quality standard for implementing inhaler regimen switch in patients with respiratory disease. Eur Respir J. 2023; 62: PA4607.

24         Gustafsson P, Taylor A, Zanen P, et al. Can patients use all dry powder inhalers equally well? Int J Clin Pract Suppl. 2005; Dec (149):13-8

25         Haughney J, Price D, Barnes NC, et al. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med. 2010; 104: 1237–1245.

26         GINA urges authorities and clinicians to consider safety for patients as well as safety for the planet. 2023; Available from: https://ginasthma.org/global-initiative-for-asthma-gina-urges-authorities-and-clinicians-to-consider-safety-for-patients-as-well-as-safety-for-the-planet/

27         Usmani OS, Bosnic-Anticevich S, Dekhuijzen R, et al. Real-World Impact of Nonclinical Inhaler Regimen Switches on Asthma or COPD: A Systematic Review. J Allergy Clin Immunol Pract. 2022; 10: 2624–2637.

28         Panigone S, Sandri F, Ferri R, et al. Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment. BMJ Open Respir Res. 2020; 7: e000751.

29         Choosing the right inhaler device for your patients. Asthma + Lung UK [Internet]. Available from: https://www.asthmaandlung.org.uk/healthcare-professionals/adult-asthma/choosing-inhaler-device

30         Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019; 15: 461–472.

31         van Boven JFM, Yorgancioglu A, Roche N, et al. Ensuring availability of respiratory medicines in times of European drug shortages. Eur Respir J. 2024; 64.

32         Keeley D, Scullion JE, Usmani OS. Minimising the environmental impact of inhaled therapies: problems with policy on low carbon inhalers. Eur Respir J. 2020; 55: 2000048.

33         Wilkinson AJK, Maslova E, Janson C, et al. Greenhouse gas emissions associated with suboptimal asthma care in the UK: the SABINA healthCARe-Based envirONmental cost of treatment (CARBON) study. Thorax. 412AD; 79.

34         Connett G, Slingo M, Sinha I, et al. Green respiratory healthcare: what really matters. Thorax. 2025; thorax-2025-223195. doi: 10.1136/thorax-2025-223195. Online ahead of print.

35         Busby J, Khezrian M, Patel S, et al. Exploring the carbon footprint of severe asthma and change after biologic therapy initiation: an analysis of Northern Irish data. ERJ open research.  2025;11(3):01009-2024

36         Alzaabi A, Bell JP, Montero-Arias F, et al. Greenhouse Gas Emissions from Respiratory Treatments: Results from the SABA CARBON International Study. Adv Ther. 2023; 40: 4836–4856.

37         Pokharel P, Lamichhane P, Pant P, et al. Factors affecting length of hospital stay in chronic obstructive pulmonary disease patients in a tertiary hospital of Nepal: A retrospective cross-sectional  study. Ann Med Surg (Lond). 2022; 80: 104246.

38         Levy ML, Bateman ED, Allan K, et al. Global access and patient safety in the transition to environmentally friendly respiratory inhalers: the Global Initiative for Asthma perspective. Lancet. 2023; 402: 1012–1016.

39         Roche N, Usmani O, Franzini L, et al. Pharmaceutical, Clinical, and Regulatory Challenges of Reformulating Pressurized Metered-Dose Inhalers to Reduce Their Environmental Impact. J Aerosol Med Pulm Drug Deliv. 2025; 38: 26–36.

40         Hydrofluorocarbon phase down in Europe. European Environment Agency [Internet]. Available from: https://www.eea.europa.eu/data-and-maps/indicators/emissions-and-consumption-of-fluorinated-3

41         Pernigotti D, Stonham C, Panigone S, et al. Reducing carbon footprint of inhalers: analysis of climate and clinical implications of different scenarios in five European countries. BMJ Open Respir Res. 2021; 8.

42         ECHA receives more than 5 600 comments on PFAS restriction proposal. 2023; . Available from: https://echa.europa.eu/-/echa-receives-5-600-comments-on-pfas-restriction-proposal

43         IPAC position paper on the proposed revision of the EU F-Gas regulation. 2022; Available from: https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/12479-Fluorinated-greenhouse-gases-review-of-EU-rules-2015-20-/F3317512_en

44         Five European states call for evidence on broad PFAS restriction. 2023; Available from: https://echa.europa.eu/-/five-european-states-call-for-evidence-on-broad-pfas-restriction

45         World Asthma Day 2025. Global Initiative for Asthma [Internet]. Available from: https://ginasthma.org/world-asthma-day-2025-2/

46         Increasing Access to Inhaled Medicines for COPD and Asthma campaign. Forum of International Respiratory Societies [Internet] 2025; Available from: https://firsnet.org/hundreds-of-millions-living-without-access-to-inhaled-medicines-for-copd-and-asthma/

47         MHRA approves world’s first low-carbon version of COPD inhaler Trixeo Aerosphere. GovUK [Internet]. Available from: www.gov.uk/government/news/mhra-approves-worlds-first-low-carbon-version-of-copd-inhaler-trixeo-aerosphere